Abstract 6074
Background
In Spain, we do not have real-time information about cancer survivors follow-up by their family doctor. The main objective of this study is to describe the characteristics and quality of life of cancer survivors followed at a primary care center in Northwest of Spain.
Methods
An individual interview was conducted with 100 survivors of breast or colon or lung cancer, all of them free of disease five or more years after their initial diagnosis. Socio-demographic variables, care plan and global quality of life assessment (using the EORTC QLQ-C30 questionnaire), were collected.
Results
We analyzed socio-demographic data of 72 women and 28 men. At the time of the interview, their median age was 66-years-old (37-99), most were married (61%), had primary studies (58%) and do not work (77 %). We analyzed aspects related to their global quality of life by using the EORTC QLQ-C30 questionnaire. A third (36%), acknowledged that their cancer diagnosis had influenced their employment status. More than 50% of survivors recognized asthenia and/or pain at the time of the interview, and at least a 15% and 20% of these cases respectively, related these symptoms to their previous diagnosis of cancer. More than a half (56%) acknowledged their previous cancer diagnosis had changed their lifes, and to a lesser extent the life of their family (28%) and economy. A 64% of the interviewed survivors considered that their enjoyed a good or a very good quality of life. Most ot the cancer survivors (75%) described themselves as cured people.
Conclusions
Most survivors recognized that their cancer diagnosis changed their lives, and up to a third of the cases also their work situation. However, the majority of survivors report a globally good quality of life and describe themselves as cured people.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Begoña Graña.
Funding
SEOM - "Oncovida" scholarship.
Disclosure
B. Grana Suarez: Research grant / Funding (institution), Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: Celgene; Research grant / Funding (institution): Roche; Travel / Accommodation / Expenses: Servier. All other authors have declared no conflicts of interest.
Resources from the same session
2171 - CCND1 Amplification Contributes to Immunosuppression in Head and Neck Squamous Cell Carcinoma and the Association with a Poor Response to Immune Checkpoint Inhibitors
Presenter: Chloe Huang
Session: Poster Display session 3
Resources:
Abstract
2624 - Efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive genes mutation
Presenter: Hui-Juan Cui
Session: Poster Display session 3
Resources:
Abstract
3494 - Neutrophil to Lymphocyte Ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N).
Presenter: Audrey Simonaggio
Session: Poster Display session 3
Resources:
Abstract
3964 - Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours
Presenter: Alexandra Pender
Session: Poster Display session 3
Resources:
Abstract
3041 - Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer Phase I IO Cohort
Presenter: Daniel Araujo
Session: Poster Display session 3
Resources:
Abstract
3910 - Analysis of Molecular Profile Complexities for Immunotherapy Decision Support
Presenter: Robert Dóczi
Session: Poster Display session 3
Resources:
Abstract
4836 - The Role of Tumor Neoantigens in the Differential Response to Immunotherapy (IO) in EGFR and BRAF Mutated Lung Cancers - Quantity or Quality?
Presenter: Katrina Case
Session: Poster Display session 3
Resources:
Abstract
1929 - Impact of previous corticosteroid (CS) exposure on efficacy of Programmed Cell Death-(Ligand) 1 blockade in patients with advanced Non-Small-Cell Lung Cancer (NSCLC): a single Center retrospective analysis
Presenter: Fabrizio Nelli
Session: Poster Display session 3
Resources:
Abstract
2601 - Comparison 18F-FDG-PET/CT criteria for prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with Ipilimumab and PD-1 inhibitors
Presenter: Sabrina Vari
Session: Poster Display session 3
Resources:
Abstract
3628 - Predictive model for survival in advanced non-small-cell lung cancer (NSCLC) treated with frontline pembrolizumab
Presenter: Xabier Mielgo Rubio
Session: Poster Display session 3
Resources:
Abstract